DL-缬氨酸丁酯 | 110470-28-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: DL-缬氨酸丁酯
• 英文名称: DL-valine butyl ester
• 英文别名: DL-Valin-butylester；Valin-butylester；Valin-butylester, Val-OBut；Butyl 2-amino-3-methylbutanoate
• CAS: 110470-28-5
• 化学式: C₉H₁₉NO₂
• 分子量: 173.255
• InChiKey: KIVHHEUXDIMERT-UHFFFAOYSA-N

物化性质

• 沸点：
  212.6±13.0 °C(Predicted)
• 密度：
  0.936±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  12
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  52.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  DL-缬氨酸丁酯 在 盐酸 作用下， 反应 35.0h， 生成 D,L-valine
  参考文献：
  名称：

  Substitution of halogen atom in ?-halonitro compounds of the aliphatic series

  摘要：

  Ethyl alpha-halo-alpha-nitropropionate and -butyrate were prepared by alkylating ammonium salts of ethyl bromo- and chloronitroacetates. The addition of alkyl acrylates to alkyl chloronitroacetates or their salts gives dialkyl alpha-chloro-alpha-nitroglutarates. Sodium salts of ethyl alpha-nitro-alpha-sulfo-beta-hydroxypropionate and -butyrate were obtained by the sulfo-dehalogenation of ethyl alpha-chloro-alpha-nitro-beta-hydroxypropionate and -butyrate with sodium dithionite. Esters of a-amino acid hydrochlorides were prepared by the reduction of alkyl alpha-chloro-alpha-nitrocarboxylates. The hydrogenation of alkyl nitrosulfoacetates leads to the corresponding disodium salts of alkyl aminodisulfoacetates and piperazine-2,5-dione.

  DOI：

  10.1007/bf00717345
• 作为产物：
  描述：

  丁酸,3-甲基-2-硝基-,丁基酯 在 palladium on activated charcoal 氢气 作用下， 以 乙醇 为溶剂， 以59%的产率得到DL-缬氨酸丁酯
  参考文献：
  名称：

  Substitution of halogen atom in ?-halonitro compounds of the aliphatic series

  摘要：

  Ethyl alpha-halo-alpha-nitropropionate and -butyrate were prepared by alkylating ammonium salts of ethyl bromo- and chloronitroacetates. The addition of alkyl acrylates to alkyl chloronitroacetates or their salts gives dialkyl alpha-chloro-alpha-nitroglutarates. Sodium salts of ethyl alpha-nitro-alpha-sulfo-beta-hydroxypropionate and -butyrate were obtained by the sulfo-dehalogenation of ethyl alpha-chloro-alpha-nitro-beta-hydroxypropionate and -butyrate with sodium dithionite. Esters of a-amino acid hydrochlorides were prepared by the reduction of alkyl alpha-chloro-alpha-nitrocarboxylates. The hydrogenation of alkyl nitrosulfoacetates leads to the corresponding disodium salts of alkyl aminodisulfoacetates and piperazine-2,5-dione.

  DOI：

  10.1007/bf00717345

文献信息

• [EN] TERMINALLY MODIFIED POLYMERS AND CONJUGATES THEREOF<br/>[FR] POLYMÈRES MODIFIÉS EN EXTRÉMITÉ ET LEURS CONJUGUÉS
  申请人：MERSANA THERAPEUTICS INC

  公开号：WO2014008375A1

  公开（公告）日：2014-01-09

  A terminally modified polymer is provided herein. At least one terminus of the polymer is -O-(CH2)2-LM or -O-CH2-CH(OH)-CH2-CR1=CR2R3. LM, R1, R2, and R3 are defined herein Also disclosed are terminal conjugates comprising the polymer and a pharmaceutically useful modifier, as well as compositions comprising the conjugates, methods of their preparation, and methods of treating various disorders with the conjugates or their compositions.

  本文提供了一种终端修饰的聚合物。聚合物的至少一个末端是-O-(CH2)2-LM或-O-CH2-CH(OH)-CH2-CR1=CR2R3。LM、R1、R2和R3在此处有定义。还披露了包括聚合物和药用修饰剂的终端共轭物，以及包括这些共轭物的组合物、它们的制备方法以及使用这些共轭物或它们的组合物治疗各种疾病的方法。
• [EN] TUBULYSIN COMPOUNDS AND CONJUGATES THEREOF<br/>[FR] COMPOSÉS DE TUBULYSINE ET LEURS CONJUGUÉS
  申请人：MERSANA THERAPEUTICS INC

  公开号：WO2014160360A1

  公开（公告）日：2014-10-02

  A tubulysin compound conjugate is provided herein. The conjugate comprises a protein based recognition-molecule (PBRM) and a polymeric carrier substituted with one or more -LD-D, the protein based recognition-molecule being connected to the polymeric carrier by Lp. Each occurrence of D is independently a tubulysin compound having a molecular weight < 5 kDa. LD and Lp are distinct linkers connecting the tubulysin compound and PBRM to the polymeric carrier respectively. Also disclosed are polymeric scaffolds useful for conjugating with a PBRM to form a polymer-tubulysin compound-PBRM conjugate described herein, compositions comprising the conjugates, methods of their preparation, and methods of treating various disorders with the conjugates or their compositions.

  本文提供了一种管状霉素化合物结合物。该结合物包括基于蛋白质的识别分子（PBRM）和与一个或多个-LD-D取代的聚合物载体，其中基于蛋白质的识别分子通过Lp连接到聚合物载体上。每个D的出现独立地是具有分子量<5 kDa的管状霉素化合物。LD和Lp是连接管状霉素化合物和PBRM到聚合物载体的不同连接物。还公开了用于与PBRM结合形成本文所述聚合物-管状霉素化合物-PBRM结合物的聚合物支架，包括结合物的组合物，其制备方法，以及使用结合物或其组合物治疗各种疾病的方法。
• [EN] PROTEIN-POLYMER-DRUG CONJUGATES<br/>[FR] CONJUGUÉS MÉDICAMENT-POLYMÈRE-PROTÉINE
  申请人：ASANA BIOSCIENCES LLC

  公开号：WO2015054669A1

  公开（公告）日：2015-04-16

  A polymeric scaffold useful for conjugating with a protein based recognition-molecule (PBRM) to form a PBRM-polymer-drug conjugate is described herein. The scaffold includes one or more terminal maleimido groups. Also disclosed is a PBRM-polymer-drug conjugate prepared from the scaffold. Compositions comprising the conjugates, methods of their preparation, and methods of treating various disorders with the conjugates or their compositions are also described.

  本文描述了一种用于与基于蛋白质的识别分子（PBRM）共轭的聚合支架，以形成PBRM-聚合物-药物共轭物的聚合支架。该支架包括一个或多个末端马来酰亚胺基团。还公开了从该支架制备的PBRM-聚合物-药物共轭物。还描述了包括这些共轭物的组合物、它们的制备方法以及使用这些共轭物或它们的组合物治疗各种疾病的方法。
• PROTEIN-POLYMER-DRUG CONJUGATES
  申请人：MERSANA THERAPEUTICS, INC.

  公开号：US20150104407A1

  公开（公告）日：2015-04-16

  A polymeric scaffold useful for conjugating with a protein based recognition-molecule (PBRM) to form a PBRM-polymer-drug conjugate is described herein. The scaffold includes one or more terminal maleimido groups. Also disclosed is a PBRM-polymer-drug conjugate prepared from the scaffold. Compositions comprising the conjugates, methods of their preparation, and methods of treating various disorders with the conjugates or their compositions are also described.

  本文描述了一种用于与基于蛋白质的识别分子（PBRM）共轭的聚合支架，形成PBRM-聚合物-药物共轭物的聚合支架。该支架包括一个或多个末端马来酰亚胺基团。还披露了从该支架制备的PBRM-聚合物-药物共轭物。还描述了包含这些共轭物的组合物、它们的制备方法以及使用这些共轭物或它们的组合物治疗各种疾病的方法。
• AMINO ACID PEPTIDE PRO-DRUGS OF PHENOLIC ANALGESICS AND USES THEREOF
  申请人：Franklin Richard

  公开号：US20090186832A1

  公开（公告）日：2009-07-23

  Prodrugs of meptazinol and other phenolic analgesics exhibiting low oral bioavailability with amino acids or lower peptides, pharmaceutical compositions containing such prodrugs and a method for providing pain relief with such prodrugs are provided. In addition, the present invention relates to methods for increasing the oral bioavailability of a phenolic analgesic. The method comprises orally administering a phenolic analgesic prodrug, wherein the phenolic analgesic is bound to an amino acid or peptide via a carbamate linkage, to a subject in need thereof. Prodrugs having side chains of valine, leucine, isoleucine and glycine amino acids and mono-, di- and tripeptides thereof are preferred.

  本发明提供了美托津诺尔及其他表现出口服生物利用度低的酚类镇痛剂的前药，其与氨基酸或较低的肽结合，以及含有这种前药的制药组合物和使用这种前药提供缓解疼痛的方法。此外，本发明还涉及提高酚类镇痛剂口服生物利用度的方法。该方法包括口服给予酚类镇痛剂前药，其中酚类镇痛剂通过氨基酸或肽的氨甲酰基链接结合到前药中，并给予需要的受试者。具有缬氨酸、亮氨酸、异亮氨酸和甘氨酸氨基酸和其单、二、三肽的侧链的前药是首选。